Sally C. Pipes is the President & CEO at the Pacific Research Institute. She focuses on health and wellness, healthcare systems, pharmaceuticals, and the intersection of medicine and insurance, often exploring topics such as patient care, pharmaceutical regulation, and healthcare administration. Sally's insights and analyses have been featured in numerous publications, including Florida Today, The San Diego Union-Tribune, and The Washington Times, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Sally C. Pipes' coverage is heavily focused on healthcare and pharmaceuticals, with a significant emphasis on policy analysis and government impact in the United States. Her articles often cite data to support her claims, indicating that she values evidence-based insights.
Given this focus, she would likely be interested in receiving pitches from experts who can provide nuanced perspectives on healthcare policies or pharmaceutical industry trends in the U.S. Pitches offering data-driven analysis of topics such as Medicaid, Obamacare, Medicare, or medical innovation are more likely to resonate with her coverage preferences.
Additionally, considering her interest in government and politics related to healthcare policy reform in the U.S., sources with expertise in health economics or public policy would also be well suited for engaging with Sally C. Pipes' content.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Sally C. Pipes
SACRAMENTO – Just weeks after California approved a record state budget of $351.7 billion for fiscal year 2026-27 that scaled back portions of its Medi-Cal expansion because of soaring costs, and as the federal government announced it was pausing $867.5 million in Medicaid payments to California, the Pacific Research Institute today released a new issue […]
By: Sally C. Pipes
The Bridge represents a long-overdue correction in Medicare's priorities. Paying for the complications of obesity while refusing to cover some of the most effective treatments for the disease itself has never made medical or economic sense.
The Trump administration has released Medicare’s proposed physician payment rule for 2027. Buried in the hundreds of pages of technical regulations is a familiar outcome — another cut in what physicians will be paid to care for seniors. Under the proposal, Medicare’s basic payment rate would fall by as much as 1.7%. That may sound […]
By: Sally C. Pipes
American doctors already know how government payment works. Private insurers pay roughly twice what Medicare does. After inflation, Medicare physician payments have fallen 33% since 2001.
The next generation of medicines won't consist only of brand-new discoveries. It will also include better versions of the medicines patients already depend on.
By: Sally C. Pipes
But while excoriating insurance companies may be good politics, forcing everyone into a government insurance monopoly would be disastrous policy
By: Sally C. Pipes
As of May, the FDA had received 990 reports of adverse events associated with compounded versions of the GLP-1 semaglutide, the active ingredient in Wegovy and Ozempic.
By: Sally C. Pipes
Americans deserve medicines that are affordable. They also deserve medicines that are safe, FDA-approved, honestly marketed and developed in a system capable of producing tomorrow's cures.
More publicly financed insurance cards do not necessarily mean better access to care. They unquestionably mean more federal money for insurers.
